CN113498417A - 多肽、其制备方法和用途 - Google Patents

多肽、其制备方法和用途 Download PDF

Info

Publication number
CN113498417A
CN113498417A CN202180001804.1A CN202180001804A CN113498417A CN 113498417 A CN113498417 A CN 113498417A CN 202180001804 A CN202180001804 A CN 202180001804A CN 113498417 A CN113498417 A CN 113498417A
Authority
CN
China
Prior art keywords
polypeptide
coronavirus
amino acid
cov
ncov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180001804.1A
Other languages
English (en)
Other versions
CN113498417B (zh
Inventor
陆路
姜世勃
夏帅
杨霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanxi Jinbo Bio Pharmaceutical Co ltd
Original Assignee
Shanxi Jinbo Bio Pharmaceutical Co ltd
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanxi Jinbo Bio Pharmaceutical Co ltd, Fudan University filed Critical Shanxi Jinbo Bio Pharmaceutical Co ltd
Publication of CN113498417A publication Critical patent/CN113498417A/zh
Application granted granted Critical
Publication of CN113498417B publication Critical patent/CN113498417B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

多肽，其包含以SEQ ID NO.1所示的氨基酸序列，属于生物医药领域，所述多肽可抑制新型冠状病毒2019‑nCoV(SARS‑CoV‑2)及类SARS病毒感染，可为2019‑nCoV以及未来有可能爆发的类SARS病毒提供了很好的预防和治疗的候选药物。还还提供了多肽衍生物，其具有棕榈酸或胆固醇修饰。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180001804.1A 2020-02-05 2021-01-11 多肽、其制备方法和用途 Active CN113498417B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020100807514 2020-02-05
CN202010080751 2020-02-05
PCT/CN2021/071078 WO2021155733A1 (zh) 2020-02-05 2021-01-11 多肽、其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113498417A true CN113498417A (zh) 2021-10-12
CN113498417B CN113498417B (zh) 2022-11-01

Family

ID=77199143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180001804.1A Active CN113498417B (zh) 2020-02-05 2021-01-11 多肽、其制备方法和用途

Country Status (6)

Country Link
US (1) US20220409694A1 (zh)
EP (1) EP4101864A4 (zh)
JP (1) JP7507244B2 (zh)
KR (1) KR20220123294A (zh)
CN (1) CN113498417B (zh)
WO (1) WO2021155733A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113908254A (zh) * 2021-10-19 2022-01-11 山西锦波生物医药股份有限公司 一种干粉吸入剂及其制备方法和用途
WO2023174122A1 (zh) * 2022-03-16 2023-09-21 北京华金瑞清生物医药技术有限公司 一种长效抑制人冠状病毒膜融合的高分子及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202307565D0 (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
CN113480619B (zh) * 2021-08-26 2023-05-09 深圳市亚辉龙生物科技股份有限公司 多肽及其在新型冠状病毒检测中的应用
CN113943375B (zh) * 2021-10-01 2022-08-16 中国科学院昆明动物研究所 一类来源于新型冠状病毒s2蛋白hr区域的重组融合蛋白及其应用
CN113908255A (zh) * 2021-10-19 2022-01-11 山西锦波生物医药股份有限公司 一种蛋白喷雾剂及其制备方法和用途
CN116375812A (zh) * 2021-12-31 2023-07-04 中国科学院微生物研究所 一种抗冠状病毒的多肽、其衍生物及其应用
CN114437196A (zh) * 2022-02-16 2022-05-06 复旦大学 一种抑制SARS-CoV-2感染的蛋白及其用途
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749558A (zh) * 2017-02-04 2017-05-31 中国医学科学院病原生物学研究所 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444044A (en) 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
US20050186575A1 (en) * 2001-05-17 2005-08-25 Rottier Petrus J.M. Corona-virus-like particles comprising functionally deleted genomes
WO2005007671A2 (en) * 2003-04-29 2005-01-27 Epitomics, Inc. Compositions and methods for treating sars
US20080027006A1 (en) * 2004-02-12 2008-01-31 The Regents Of The University Of Colorado Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity
CN107022008B (zh) * 2016-01-30 2021-04-23 山西锦波生物医药股份有限公司 广谱地抑制人类冠状病毒感染的多肽及其应用
AU2018241252A1 (en) * 2017-03-30 2019-10-03 The University Of Queensland Chimeric molecules and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749558A (zh) * 2017-02-04 2017-05-31 中国医学科学院病原生物学研究所 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIU，S.W. ET AL.: "Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors", 《LANCET》 *
LU，L. ET AL.: "Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor", 《NATURE COMMUNICATIONS》 *
XIA，S. ET AL.: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike", 《SCIENCE ADVANCES》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113908254A (zh) * 2021-10-19 2022-01-11 山西锦波生物医药股份有限公司 一种干粉吸入剂及其制备方法和用途
CN113908254B (zh) * 2021-10-19 2024-05-28 山西锦波生物医药股份有限公司 一种干粉吸入剂及其制备方法和用途
WO2023174122A1 (zh) * 2022-03-16 2023-09-21 北京华金瑞清生物医药技术有限公司 一种长效抑制人冠状病毒膜融合的高分子及其应用

Also Published As

Publication number Publication date
CN113498417B (zh) 2022-11-01
WO2021155733A1 (zh) 2021-08-12
US20220409694A1 (en) 2022-12-29
JP2023512191A (ja) 2023-03-24
EP4101864A4 (en) 2023-09-20
EP4101864A1 (en) 2022-12-14
KR20220123294A (ko) 2022-09-06
JP7507244B2 (ja) 2024-06-27

Similar Documents

Publication Publication Date Title
CN113498417B (zh) 多肽、其制备方法和用途
CN107022008B (zh) 广谱地抑制人类冠状病毒感染的多肽及其应用
JP6357487B2 (ja) 安定化ヒト免疫不全ウイルス（ｈｉｖ）エンベロープ（ｅｎｖ）トリマーワクチン及びそれを使用する方法
CN113563433B (zh) 多肽、其制备方法和用途
CN113663073A (zh) 一种靶向s蛋白棕榈酰化的多肽在制备广谱抗冠状病毒药物中的应用
US20230348880A1 (en) Soluble ace2 and fusion protein, and applications thereof
CN101678125A (zh) 用于递送抗病毒肽治疗剂的新制剂
EP3666790A1 (en) Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
US20210093709A1 (en) Use of shrek proteins for inactivating viral infectivity and to produce live-attenuated vaccines against viruses
ES2780525T3 (es) Proteínas quiméricas basadas en cyaa que comprenden un polipéptido heterólogo y sus usos en la inducción de respuestas inmunes
CN113398260A (zh) 以痘苗病毒为载体的新冠疫苗
EP3342866B1 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
CN112023045A (zh) 抑制masp-2及其下游补体活化效应的物质在制备冠状病毒所致疾病药物中的应用
WO2021164576A1 (zh) 用于抗冠状病毒感染的药物及其应用
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
CN109476708B (zh) 针对致关节炎甲病毒的疫苗
EP3624825A1 (en) Recombinant oncolytic virus
WO2008100122A1 (en) Oligomerizaed protein transduction domains, a method for preparing the same and an intracellular transduction method using the same
WO2023064993A1 (en) Chimeric betacoronavirus spike polypeptides
CN102596222B (zh) 作为肿瘤生长的抑制剂的皮抑菌肽b2
EP1290017A2 (en) Compositions and methods for delivery of a molecule into a cell
WO2005016247A2 (en) Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars
CN113559239B (zh) 融合蛋白在制备预防和/或治疗呼吸道疾病的药物中的应用
US11155582B2 (en) Antiviral peptide and use thereof
CN116440285A (zh) 冠状病毒多肽类融合抑制剂的长效化的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058869

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20220419

Address after: 030032 No.18, Jinbo street, Taiyuan Tanghuai Park, Shanxi comprehensive reform demonstration zone, Taiyuan City, Shanxi Province

Applicant after: SHANXI JINBO BIO-PHARMACEUTICAL Co.,Ltd.

Address before: 200433 No. 220, Handan Road, Shanghai, Yangpu District

Applicant before: FUDAN University

Applicant before: SHANXI JINBO BIO-PHARMACEUTICAL Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant